Baseline PECOS Data Show Symptom Burden Persists After Pediatric SARS-CoV-2 Infection
The first baseline analysis from the PECOS cohort places a clinical marker on a problem pediatric clinicians have faced since the pandemic began: many children and adolescents with prior SARS-CoV-2 infection are reporting more symptoms than uninfected peers, even before the study moves into its longitudinal phase. In this cross-sectional comparison, 654 participants aged 0 to 21 years completed baseline visits by June 30, 2023, including 541 in the infected cohort and 113 in the uninfected cohort. The design matters because it does not ask whether long COVID exists in theory; it asks how symptom burden, function, and parent-reported health look in a large, multicenter pediatric population at the start of follow-up.
Constitutional complaints were more common in the infected group, and the same pattern extended across multiple symptom domains. Odds ratios favored higher reporting of constitutional symptoms, HEENT symptoms, respiratory symptoms, and gastrointestinal symptoms among infected participants, with ORs of 2.24, 3.74, 2.41, and 2.58, respectively. Those differences sketch a broad multisystem phenotype rather than a narrow post-viral complaint. In a child who is trying to return to school, sports, and family routines, persistent fatigue, cough, abdominal symptoms, or upper-airway complaints can translate directly into missed class time, lower stamina, and less predictable daily functioning.
One result stands out immediately: cardiopulmonary testing did not separate the two groups in the same way symptom questionnaires did.
Symptom Reports Outpaced Objective Cardiopulmonary Findings
Cardiopulmonary findings were similar between cohorts, despite the heavier symptom burden reported by infected participants. That disconnect is clinically familiar in post-infectious syndromes. Symptoms such as fatigue, reduced exercise tolerance, dyspnea, or chest discomfort can reflect inflammatory, autonomic, neurocognitive, or deconditioning-related pathways without producing obvious abnormalities on standard cardiopulmonary evaluation at a single visit. A normal or near-normal exam does not erase the patient’s experience; it does, however, shape the next step in evaluation by narrowing the likelihood of structural cardiopulmonary disease as the explanation for every complaint.
The population-level signal is important because pediatric post-COVID care often sits at the intersection of reassurance and vigilance. If standard cardiopulmonary testing is broadly similar while symptom burden remains elevated, clinicians may need to think beyond organ-specific injury and consider broader post-viral syndromes, sleep disruption, autonomic symptoms, activity limitation, and psychosocial strain. The baseline data do not resolve causality, but they do support continued surveillance for functional impairment even when objective testing is unrevealing.
Patient-Reported Outcomes Captured the Day-to-Day Cost
The patient-reported outcome data gave the clearest picture of daily impact. Infected participants had worse scores in Pain, Fatigue, Global Health, Physical Functioning, Cognitive Functioning, Mobility, and Sleep Disturbance when compared with uninfected controls. Six of ten Patient Reported Outcome Measures domains were significantly worse in the infected cohort, a spread that reaches well beyond a single symptom category and into areas that families recognize immediately at home and school. Cognitive functioning and sleep are especially consequential in pediatrics because they affect attention, learning, memory, mood regulation, and the capacity to participate in normal developmental demands.
The clinical meaning is straightforward. A child who is tired, sleeping poorly, in pain, and less able to sustain concentration may not look acutely ill in clinic, yet still experience a real decrement in function. In pediatric practice, that gap between a normal-appearing examination and a diminished quality of life can delay recognition of long-term sequelae unless clinicians ask directly about energy, cognition, sleep, and school performance.
These data also reinforce why parent-reported and child-reported outcomes belong in the same conversation as physical examination and cardiopulmonary testing. Functional impairment is not always visible in a brief office encounter. The study design captured that reality by pairing symptom review with validated psychological and developmental surveys, giving the cohort a broader lens than a single biomarker or imaging study could provide.
A Multicenter Cohort Built for Longitudinal Answers
PECOS was designed as a large, diverse, prospective, longitudinal, multicenter cohort with a planned 3-year follow-up. Participants with laboratory-confirmed SARS-CoV-2 infection were enrolled into the infected group, while uninfected participants had no history or laboratory evidence of infection. That structure gives the study a strong foundation for future comparisons, including how symptom burden evolves, which children recover, and whether biological or genetic factors track with persistent sequelae. The current analysis is cross-sectional, so it establishes association rather than trajectory, but the cohort architecture is built to answer the more difficult questions that follow: who improves, who remains symptomatic, and what immunologic or developmental features may shape those paths.
The age range, spanning infancy through young adulthood, also broadens the clinical relevance. Pediatric SARS-CoV-2 outcomes do not cluster in only one developmental stage, and a study that includes children, adolescents, and young adults can better reflect the real-world continuum of post-infectious follow-up. A prospective multicenter design may also reduce the chance that a single practice environment or a single referral pattern explains the findings.
What the Baseline Signal Means for Pediatric Practice
The baseline PECOS results support a practical message for clinicians: prior SARS-CoV-2 infection in children and adolescents may be followed by a higher burden of persistent symptoms and worse day-to-day functioning, even when cardiopulmonary testing does not show major group differences. In practice, that means the clinic conversation should not stop at a normal exam or a reassuring test result. Children with ongoing fatigue, pain, sleep disturbance, respiratory complaints, or cognitive difficulty may need structured follow-up that includes school functioning, activity tolerance, and mental health screening alongside conventional medical review.
Because the cohort remains ongoing, the most valuable information is still ahead. Future visits can clarify which symptom patterns persist, how often objective abnormalities emerge, and whether immune or genetic markers help explain why some children carry a heavier post-infectious burden than others. The baseline data are already enough to show that the problem is measurable; the longitudinal phase will determine how durable it is and which children are most at risk for prolonged impairment.